# Miguel A. Sanz

Source: https://onco.cc/people/miguel-sanz/  
OnCo record `miguel-sanz` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Spanish haematologist who led the PETHEMA trials that tailored acute promyelocytic leukaemia treatment to relapse risk, and who chaired the European LeukemiaNet recommendations for the disease.

## Summary

Miguel Sanz is a haematologist at Hospital La Fe in Valencia and a founder of the Spanish PETHEMA cooperative group. He led the PETHEMA LPA trials that established risk-adapted ATRA and anthracycline therapy for acute promyelocytic leukaemia and defined the Sanz risk score based on white cell and platelet counts. He was first author of the 2019 Blood update of the European LeukemiaNet recommendations for managing the disease.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: leukaemia; guidelines
- Role: Haematologist, Hospital Universitari i Politècnic La Fe, Valencia
- Specialisms: Acute promyelocytic leukaemia; Risk-adapted therapy; PETHEMA trials

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Acute promyelocytic leukaemia](https://onco.cc/cancers/apl/)
- institutions: [Hospital Universitari i Politècnic La Fe](https://onco.cc/institutions/la-fe-valencia/)
- key papers: [European LeukemiaNet recommendations for the management of acute promyelocytic leukaemia (2019 update)](https://onco.cc/key-papers/paper-eln-apl-sanz-blood-2019/)

---
JSON: https://onco.cc/api/v1/entities/miguel-sanz.json